Archive · 15 Aug 2025
Glenmark Pharma Q1 Profit Plummets 86% on US Litigation Settlement
Glenmark Pharmaceuticals' profit went way down, about 86%, in the first part of the year.
This happened because they had to set aside a lot of money to pay for a legal case in the US.
Even though the company made about the same amount of money from selling its products as last year, the legal costs affected their profit.
They are settling a case about claims of unfair pricing and market practices.
The company is growing in the US market.
Glenmark Pharmaceuticals' profit after tax (PAT) decreased by 86% in Q1 FY26.
The decline was due to a provision for a US litigation settlement.
Total revenue from operations slightly increased year-over-year.
The company made a provision of ₹323.23 crore for settling the US litigation.
Glenmark reported growth in its US business.
- Who
- Glenmark Pharmaceuticals Ltd.
- What
- Glenmark Pharmaceuticals reported an 86% drop in profit due to a US litigation settlement provision.
- When
- Q1 FY26, ended June 30, 2025.
- Where
- India, with operations and litigation in the US.
- Why
- To announce the company's financial performance and settle the US litigation.
- PAT Decline
- 86%
- Q1 FY26 PAT
- ₹46.97 crore
- Q1 FY25 PAT
- ₹340.24 crore
- Revenue from Operations
- ₹3,264.44 crore
- Litigation Settlement Provision
- ₹323.23 crore
